Alpha Mannosidosis Market

USD 41.2 million in 2026 to USD 107.8 million by 2036 at a 10.1% CAGR.

• As per Fact.MR analysis, the alpha mannosidosis market was valued at USD 37.5 million in 2025
• Demand will grow from USD 41.2 million in 2026 to USD 107.8 million by 2036.
• The forecast records a 10.1% CAGR from 2026 to 2036 as enzyme replacement therapy access, rare-disease diagnosis, and specialist treatment pathways influence market expansion.

Source: Fact.MR analysis. Updated Oct 28, 2026

What are the defining numbers behind Alpha Mannosidosis Market growth?

USD 66.6 million absolute opportunity between 2026 and 2036.

• Demand Drivers in the Market
  • Availability of enzyme replacement therapy drives the alpha mannosidosis market by providing a targeted treatment for eligible patients. Australia's Therapeutic Goods Administration (TGA) registered Lamzede (velmanase alfa) on March 26, 2025, for enzyme replacement therapy targeting non-central nervous system manifestations in patients with alpha-mannosidosis. This regulatory milestone expanded the treatment’s availability in Australia for eligible patients, supporting access to enzyme replacement therapy and contributing to the development of the alpha mannosidosis treatment market. [1]. [1]
  • Greater emphasis on rare-disease diagnosis supports the alpha mannosidosis market by improving the identification of patients with symptoms such as hearing impairment, recurrent infections, skeletal abnormalities, and muscle weakness.
  • Specialist care requirements support the alpha mannosidosis market by increasing demand for coordinated long-term management involving metabolic disease specialists, genetic services, and other healthcare professionals.
• Key Segments Analyzed
  • By Treatment Type: Enzyme Replacement Therapy will account for 58.2% of the market in 2026, reflecting the importance of velmanase alfa in the available treatment landscape.
  • By Disease Type: Type I segment holds 52.1% share in 2026.
  • By End-User: Hospitals represents 62.4% share in 2026, reflecting specialist supervision, intravenous treatment administration, and multidisciplinary patient management.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, states, “The alpha mannosidosis market depends on identifying eligible patients and maintaining access to specialist treatment. Enzyme replacement therapy provides an established option for certain disease manifestations, while diagnosis, treatment eligibility, and long-term follow-up remain important considerations.”
• Strategic Implications
  • Manufacturers need to communicate approved indications, treatment administration requirements, safety information, and eligibility criteria clearly.
  • Healthcare providers require diagnostic pathways that combine clinical assessment with enzyme testing and molecular genetic analysis.
  • Market access teams should address reimbursement, infusion access, and continuity of treatment for eligible patients.
  • Research teams must evaluate emerging therapeutic approaches without treating investigational candidates as approved treatments.
  • Commercial forecasts must account for the very small patient population, country-specific access, and uncertainty associated with rare-disease revenue estimates.

Germany is set to record an 8.2% CAGR through 2036. Brazil is set to post 7.4%, followed by the USA at 9.5%. The UK is estimated to advance at 11.5%, while Japan is forecast at 12.5%.

Fact.MR finds that Enzyme Replacement Therapy leads Treatment Type at 58.2%; Type I leads Disease Type at 52.1%; and Hospitals leads End-User at 62.4%.

Which Treatment Type dominates?

Enzyme Replacement Therapy is set to hold 58.2% share in 2026.

Source: Fact.MR analysis. Updated Oct 28, 2026

Enzyme replacement therapy is an established treatment option for eligible patients with alpha mannosidosis. Lamzede contains velmanase alfa and is administered by intravenous infusion. Its authorized use addresses non-neurological manifestations, and it does not resolve every effect of the disease. Treatment decisions remain dependent on clinical eligibility and specialist supervision.

What leads the Disease Type segment?

Type I is set to represent 52.1% share in 2026.

Source: Fact.MR analysis. Updated Oct 28, 2026

Alpha mannosidosis has a variable clinical presentation. GeneReviews describes mild, moderate, and severe forms, with differences in age at onset, progression, and clinical features. The European Medicines Agency describes mild (type 1), moderate (type 2), and severe (type 3) clinical forms of alpha-mannosidosis. Fact.MR disease-type revenue shares require a clearly specified market segmentation methodology and should not be interpreted as prevalence estimates [2]. [2]

How does End-User shape demand?

Hospitals are likely to account for 62.4% share in 2026.

Source: Fact.MR analysis. Updated Oct 28, 2026

The hospitals segment holds prominent end-user share in the alpha mannosidosis market due to the need for specialist diagnosis, multidisciplinary clinical evaluation, and supervised enzyme replacement therapy administration. Hospitals provide intravenous infusion facilities, monitor potential treatment-related reactions, and coordinate long-term patient management. Access to metabolic disease specialists and diagnostic services further supports hospital-based treatment delivery.

Enzyme replacement therapy and improved rare-disease identification support demand, while the small patient population and treatment access constraints limit expansion.

Drivers Impact Analysis

Source: Fact.MR analysis. Updated Oct 28, 2026

Opportunity Impact Analysis

Source: Fact.MR analysis. Updated Oct 28, 2026

Restraints Impact Analysis

Source: Fact.MR analysis. Updated Oct 28, 2026

Source: Fact.MR analysis. Updated Oct 28, 2026

What supports Germany adoption?

8.2% CAGR, supported by rare-disease diagnosis and access to specialist treatment.

Germany's alpha mannosidosis market depends on identifying eligible patients, access to metabolic disease specialists, and reimbursement for treatment. Lamzede (velmanase alfa) received European Union marketing authorisation on March 23, 2018, for non-neurological manifestations in patients with mild-to-moderate alpha-mannosidosis, providing an approved option for eligible patients. Diagnosis rates, specialist capacity, and treatment access will influence market adoption.

How is Brazil developing alpha mannosidosis adoption?

7.4% CAGR, driven by treatment registration and improving rare-disease care pathways.

Brazil's alpha mannosidosis market depends on improved identification of patients with this rare genetic disorder and access to metabolic disease specialists. Wider availability of genetic testing, better referral pathways, and treatment funding can help eligible patients access enzyme replacement therapy. Healthcare access and infusion-service availability will influence market growth.

What supports United States adoption?

9.5% CAGR, shaped by demand for disease-specific treatment and long-term patient management.

The US alpha mannosidosis market is supported by demand for enzyme replacement therapy, specialist consultations, and ongoing clinical monitoring. Greater awareness of rare diseases and improved diagnostic capabilities can help identify eligible patients. Insurance coverage, treatment affordability, and access to infusion services will influence therapy adoption and overall market growth.

How is the United Kingdom building adoption?

11.5% CAGR, led by specialist treatment pathways.

The UK alpha-mannosidosis market has growth potential through improved genetic testing, earlier diagnosis, and coordinated specialist care. England's 2026 Rare Diseases Action Plan reported that the NHS Genomic Medicine Service performed more than 340,000 genomic tests for rare diseases in 2025. This measures broader rare-disease diagnostic capacity rather than testing specifically for alpha-mannosidosis. These initiatives may improve patient identification and referral for eligible treatments, although access to therapy and the small patient population remain important constraints [5].  [5]

What supports Japan adoption?

12.5% CAGR, shaped by potential treatment-access opportunities.

Japan's opportunity depends on identifying eligible patients and ensuring access to specialist treatment and follow-up. As with other countries, the small patient population means that individual treatment decisions, access arrangements, and the timing of diagnosis can materially influence annual revenue. Japan's treatment-access outlook depends on the confirmed regulatory status of velmanase alfa, applicable reimbursement arrangements, and specialist treatment availability. A Japan-specific regulatory milestone requires confirmation from the responsible regulator. Commercial adoption will depend on regulatory approval, reimbursement, and access to specialist services [3] [4][3][4]

Fact.MR finds that Chiesi Farmaceutici S.p.A., Fondazione Telethon ETS, Kamada Ltd. and Key2Brain AB are profiled in the alpha-mannosidosis treatment landscape. Chiesi Farmaceutici S.p.A. holds the marketing authorization for Lamzede (velmanase alfa), an enzyme replacement therapy approved for non-neurological manifestations of alpha-mannosidosis. Kamada lists Lamzede in its product distribution portfolio.

Competition in this market is shaped by treatment availability, regulatory approvals, patient access and the ability to support long-term therapy for a very small patient population. Product development and commercialization roles differ across the companies, so historical developers, distribution partners and organizations involved in research should not automatically be classified as active manufacturers.

Key companies profiled in the Alpha Mannosidosis Market include Chiesi Farmaceutici S.p.A.; Fondazione Telethon ETS; Kamada Ltd.; and Key2Brain AB.

• Chiesi Farmaceutici S.p.A.
• Fondazione Telethon ETS
• Kamada Ltd.
• Key2Brain AB

• [1] Therapeutic Goods Administration. (2025, March 26). LAMZEDE (Chiesi Australia Pty Ltd). Australian Government Department of Health, Disability and Ageing.
• Official TGA source
• [2] Ficicioglu, C., & Stepien, K. M. (2024, June 13). Alpha-mannosidosis. In GeneReviews®. University of Washington, Seattle.
• NCBI GeneReviews source
• [3] Ministry of Health, Labour and Welfare. (2026, May 18).[Designation, cancellation of designation, and related matters for orphan drugs].
• Official MHLW source
• [4] Ministry of Health, Labour and Welfare. (2026, April 24). 2026[Minutes of the Pharmaceutical Affairs Council, First Committee on Drugs, April 24, 2026].
• Official MHLW minutes
• [5] Department of Health and Social Care. (2026, April 14). England Rare Diseases Action Plan 2026: Main report. GOV.UK.
• Official GOV.UK report

• The report estimates the alpha mannosidosis market's 2026 valuation and 2036 forecast.
• Segment analysis compares the specified treatment types, disease classifications, and end-users.
• Country analysis discusses Germany, Brazil, the USA, the UK, and Japan
• The competitive overview identifies the named pharmaceutical companies while distinguishing direct product evidence from broader rare-disease activity.
• Treatment analysis discusses enzyme replacement therapy, transplantation, and emerging therapeutic approaches.

The market covers pharmaceutical treatments and associated treatment categories intended for patients with alpha mannosidosis. It focuses on enzyme replacement therapy and other specified treatment approaches, alongside the end-user settings in which eligible patients receive care. Market demand depends on diagnosis, clinical eligibility, regulatory authorisation, reimbursement, and access to specialist services.

What is included in the scope?

Included products and services relate to the defined treatment market for alpha mannosidosis. The analysis covers the specified treatment categories, disease-type classifications, end-users, geographic markets, and company profiles. Commercial revenue estimates should distinguish approved medicines from investigational therapies and historical development programmes.

What is excluded from the scope?

The analysis excludes treatments intended exclusively for unrelated lysosomal storage disorders and general pharmaceutical products without a specific alpha mannosidosis indication.

Unrelated hospital services, diagnostic equipment revenue, and general genetic testing revenue are excluded unless explicitly incorporated into the market definition. Investigational products are not counted as approved commercial treatments.

How Was the Analysis Built?

The analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews.

• Primary Research: Primary research includes discussions with manufacturers, service providers, technology developers, distributors, end users, and subject-matter experts. These conversations examine purchasing priorities, product adoption, operational challenges, approval requirements, competitive positioning, and the factors that influence wider market acceptance.
• Desk Research: Desk research covers government statistics, regulatory publications, company filings, trade data, technical studies, industry associations, standards, public policy, and other authoritative sources. Every source used in the analysis is documented in the bibliography.
• Market Sizing and Forecasting: Market estimates combine historical performance, demand indicators, pricing and volume trends, segment shares, company participation, country-level growth, adoption patterns, investment activity, and barriers to market expansion.
• Data Validation and Update Cycle: Findings are validated by comparing primary interviews with public data, company activity, regulatory changes, trade patterns, and industry developments. Regular updates review new product launches, capacity changes, partnerships, approvals, and shifts in commercial adoption.